PMID- 29912759
OWN - NLM
STAT- MEDLINE
DCOM- 20200423
LR  - 20221207
IS  - 1539-2031 (Electronic)
IS  - 0192-0790 (Linking)
VI  - 53
IP  - 2
DP  - 2019 Feb
TI  - Real-World Study on Sofosbuvir-based Therapies in Asian Americans With Chronic 
      Hepatitis C.
PG  - 147-154
LID - 10.1097/MCG.0000000000001078 [doi]
AB  - BACKGROUND: Limited data exist with regard to treatment outcomes in Asian 
      Americans with chronic hepatitis C (CHC). We evaluated sofosbuvir (SOF)-based 
      regimens in a national cohort of Asian Americans. METHODS: Eligible Asian 
      Americans patients with CHC who had posttreatment follow-up of 24 weeks for SOF 
      -based therapies from December 2013 to June 2017 were enrolled from 11 sites 
      across the United States. The primary endpoint was sustained virologic response 
      (SVR) rates at posttreatment weeks 12 and 24. Secondary endpoints were to 
      evaluate safety by tolerability and adverse events (AEs). RESULTS: Among 231 
      patients screened, 186 were enrolled. At baseline, 31% (57/186) patients were 
      cirrhotic, 34% (63/186) were treatment experienced. Most of the subjects (42%, 
      79/186) received ledispavir/SOF therapy. The overall SVR12 was 95%, ranging from 
      86% in genotype (GT) 1b on SOF+ribavirin to 100% in GT 1b patients on 
      ledipasvir/SOF at subgroup analyses. SVR12 was significantly lower in cirrhotic 
      than in noncirrhotic patients [88% (50/57) vs. 98% (126/129), P<0.01]. Stratified 
      by GT, SVR12 were: 96% (43/45) in GT 1a; 93% (67/72) in GT 1b; 100% (23/23) in GT 
      2; 90% (19/21) in GT 3; 100% (1/1) in GT 4; 83% (5/6) in GT 5; and 100% (16/16) 
      in GT 6. Cirrhotic patients with treatment failure were primarily GT 1, (GT 1a, 
      n=2; GT 1b, n=4) with 1 GT 5 (n=1). Patients tolerated the treatment without 
      serious AEs. Late relapse occurred in 1 patient after achieving SVR12. 
      CONCLUSIONS: In Asian Americans with CHC, SOF-based regimens were well tolerated 
      without serious AEs and could achieve high SVR12 regardless of hepatitis C viral 
      infection GT.
FAU - Pan, Calvin Q
AU  - Pan CQ
AD  - Department of Medicine, Division of Gastroenterology and Hepatology, NYU Langone 
      Health, NYU School of Medicine.
AD  - Beijing Youan Hospital, Capital Medical University, Beijing, China.
FAU - Tiongson, Benjamin C
AU  - Tiongson BC
AD  - Interfaith Medical Center.
AD  - University of the East Ramon Magsaysay Memorial Medical Center Inc., Quezon City, 
      NCR, Philippines.
FAU - Hu, Ke-Qin
AU  - Hu KQ
AD  - Division of Gastroenterology and Hepatology, University of California, Irvine, 
      School of Medicine, Orange.
FAU - Han, Steven-Huy B
AU  - Han SB
AD  - Pfleger Liver Institute, David Geffen School of Medicine at UCLA.
FAU - Tong, Myron
AU  - Tong M
AD  - Division of Gastroenterology and Hepatology, Huntington Medical Research 
      Institutes, Pasadena, CA.
FAU - Chu, Danny
AU  - Chu D
AD  - Downtown Gastroenterology PC, New York.
FAU - Park, James
AU  - Park J
AD  - Department of Medicine, Division of Gastroenterology and Hepatology, NYU Langone 
      Health, NYU School of Medicine.
FAU - Lee, Tai Ping
AU  - Lee TP
AD  - Division of Hepatology, Sandra Atlas Bass Center for Liver Disease, Donald and 
      Barbara Zucker School of Medicine at Hofstraa/Northwell Health, Manhasset.
FAU - Bhamidimarri, Kalyan Ram
AU  - Bhamidimarri KR
AD  - Transplant Hepatology, University of Miami Miller School of Medicine, Miami, FL.
FAU - Ma, Xiaoli
AU  - Ma X
AD  - Division of Gastroenterology and Hepatology, Hahnemann University Hospital, 
      Drexel College of Medicine, Philadelphia, PA.
FAU - Xiao, Pei Ying
AU  - Xiao PY
AD  - Division of Gastroenterology and Hepatology, SUNY Downstate Medical Center.
FAU - Mohanty, Smruti R
AU  - Mohanty SR
AD  - Division of Gastroenterology and Hepatology, NewYork-Presbyterian Brooklyn 
      Methodist Hospital, Brooklyn.
FAU - Wang, Dan
AU  - Wang D
AD  - Saint Johns University, Jamaica, NY.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Clin Gastroenterol
JT  - Journal of clinical gastroenterology
JID - 7910017
RN  - 0 (Antiviral Agents)
RN  - 0 (Benzimidazoles)
RN  - 0 (Fluorenes)
RN  - 0 (ledipasvir, sofosbuvir drug combination)
RN  - 49717AWG6K (Ribavirin)
RN  - E2OU15WN0N (Uridine Monophosphate)
RN  - WJ6CA3ZU8B (Sofosbuvir)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antiviral Agents/*administration & dosage
MH  - *Asian
MH  - Benzimidazoles/administration & dosage
MH  - Cohort Studies
MH  - Drug Therapy, Combination
MH  - Female
MH  - Fluorenes/administration & dosage
MH  - Follow-Up Studies
MH  - Genotype
MH  - Hepacivirus/genetics/isolation & purification
MH  - Hepatitis C, Chronic/*drug therapy/virology
MH  - Humans
MH  - Liver Cirrhosis/complications
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Ribavirin/administration & dosage
MH  - Sofosbuvir/*administration & dosage
MH  - Sustained Virologic Response
MH  - Treatment Outcome
MH  - Uridine Monophosphate/administration & dosage/analogs & derivatives
MH  - Young Adult
EDAT- 2018/06/19 06:00
MHDA- 2020/04/24 06:00
CRDT- 2018/06/19 06:00
PHST- 2018/06/19 06:00 [pubmed]
PHST- 2020/04/24 06:00 [medline]
PHST- 2018/06/19 06:00 [entrez]
AID - 10.1097/MCG.0000000000001078 [doi]
PST - ppublish
SO  - J Clin Gastroenterol. 2019 Feb;53(2):147-154. doi: 10.1097/MCG.0000000000001078.